TrialPloS one2015

Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.

Jorge Eduardo Toblli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.